CTX213
Live / Applied — First extension granted (statement of use) (as of 12 Mar 2026)
What this means for you
Not registered yet, but its 13 Jan 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98955696
- Mark type
- Stylized text
- Filed
- 13 Jan 2025
- Published for opposition
- 29 Jul 2025
- Attorney of record
- Tiffany D. Gehrke
Goods and services
- Class 005 — Pharmaceuticals: Cells for medical or clinical use in the field of stem cell therapy for the treatment of diabetes; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of diabetes; pharmaceutical and biopharmaceutical agents for the treatment of diabetes
- Class 042 — Scientific and technological services: gene editing, namely, pharmaceutical research and development in the field of stem cell therapy for the treatment of diabetes; Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of stem cell therapy for the treatment of diabetes
Owner
- CRISPR Therapeutics AG, ZUG V8, CH
- CRISPR Therapeutics AG, ZUG V8, CH
Prosecution history
- 13 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Mar 2026 — SOU EXTENSION 1 GRANTED
- 12 Mar 2026 — SOU EXTENSION 1 FILED
- 12 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 23 Sept 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 29 Jul 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 29 Jul 2025 — PUBLISHED FOR OPPOSITION
- 23 Jul 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 24 Jun 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 21 Jun 2025 — ASSIGNED TO EXAMINER
- 10 Jun 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 13 Jan 2025 — APPLICATION FILING RECEIPT MAILED
- 13 Jan 2025 — NEW APPLICATION ENTERED